Fenfluramine

CHEMBL87493 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
231.3 g/mol
LogP
3.4
Phase
4

This medication was re-approved at very low doses specifically to reduce seizure frequency in rare childhood epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. It works through serotonin signaling pathways and specific receptors in the brain.

Khối lượng phân tử

231,2600 g/mol

LogP

3,40

TPSA

12,00 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCNC(C)Cc1cccc(C(F)(F)F)c1

InChI

InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3

Molecular Formula

C12H16F3N

HBD / HBA

1 / 4

Liên kết có thể quay

4

Nguyên tử nặng

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This medication was re-approved at very low doses specifically to reduce seizure frequency in rare childhood epilepsies such as Dravet syndrome and Lennox-Gastaut syndrome. It works through serotonin signaling pathways and specific receptors in the brain.

Yes, Fenfluramine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL87493. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3337. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.